CL2007003501A1 - Un compuesto (e)-n-{3-[1-(8-cloro-11h-10-oxa-1-aza-dibenzo[a,d]ciclohepten-5-iliden)propil]-fenil}-metansulfonamida o una sal del mismo; composicion farmaceutica; y uso para el tratamiento de artritis reumatoide, asma, epoc, entre otras. - Google Patents

Un compuesto (e)-n-{3-[1-(8-cloro-11h-10-oxa-1-aza-dibenzo[a,d]ciclohepten-5-iliden)propil]-fenil}-metansulfonamida o una sal del mismo; composicion farmaceutica; y uso para el tratamiento de artritis reumatoide, asma, epoc, entre otras.

Info

Publication number
CL2007003501A1
CL2007003501A1 CL200703501A CL2007003501A CL2007003501A1 CL 2007003501 A1 CL2007003501 A1 CL 2007003501A1 CL 200703501 A CL200703501 A CL 200703501A CL 2007003501 A CL2007003501 A CL 2007003501A CL 2007003501 A1 CL2007003501 A1 CL 2007003501A1
Authority
CL
Chile
Prior art keywords
metansulphonamide
cyclhepten
iliden
penyl
dibenzo
Prior art date
Application number
CL200703501A
Other languages
English (en)
Spanish (es)
Inventor
William Carson Y Micha Matthew
Original Assignee
Eli Lilly And Company Soc Orga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company Soc Orga filed Critical Eli Lilly And Company Soc Orga
Publication of CL2007003501A1 publication Critical patent/CL2007003501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL200703501A 2006-07-14 2007-12-05 Un compuesto (e)-n-{3-[1-(8-cloro-11h-10-oxa-1-aza-dibenzo[a,d]ciclohepten-5-iliden)propil]-fenil}-metansulfonamida o una sal del mismo; composicion farmaceutica; y uso para el tratamiento de artritis reumatoide, asma, epoc, entre otras. CL2007003501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83116606P 2006-07-14 2006-07-14
PCT/US2007/073345 WO2008008882A2 (en) 2006-07-14 2007-07-12 Glucocorticoid receptor modulator and methods of use

Publications (1)

Publication Number Publication Date
CL2007003501A1 true CL2007003501A1 (es) 2008-07-04

Family

ID=38924180

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703501A CL2007003501A1 (es) 2006-07-14 2007-12-05 Un compuesto (e)-n-{3-[1-(8-cloro-11h-10-oxa-1-aza-dibenzo[a,d]ciclohepten-5-iliden)propil]-fenil}-metansulfonamida o una sal del mismo; composicion farmaceutica; y uso para el tratamiento de artritis reumatoide, asma, epoc, entre otras.

Country Status (14)

Country Link
US (1) US8101760B2 (enExample)
EP (1) EP2043646B1 (enExample)
JP (1) JP5189091B2 (enExample)
KR (1) KR20090020694A (enExample)
CN (1) CN101489556A (enExample)
AU (1) AU2007272504B2 (enExample)
BR (1) BRPI0714811A2 (enExample)
CA (1) CA2655202A1 (enExample)
CL (1) CL2007003501A1 (enExample)
EA (1) EA014695B1 (enExample)
ES (1) ES2384057T3 (enExample)
MX (1) MX2009000583A (enExample)
TW (1) TW200902537A (enExample)
WO (1) WO2008008882A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
ES2370148T3 (es) 2008-01-11 2011-12-13 Eli Lilly & Company (e)-n-{3-[fluoro-11h-10-oxa-1-aza-dibenzo-[a,d]-ciclohepten-5-iliden)-propil]-fenil}-metilsulfonamida como modulador del receptor de glucocorticoides para el tratamiento de artritis reumatoide.
UY31831A (es) 2008-05-20 2010-01-05 Astrazeneca Ab Derivados de indazoles sustituidos con fenilo o piridinilo
JPWO2010001990A1 (ja) 2008-07-03 2011-12-22 協和発酵キリン株式会社 四環系化合物
WO2011081173A1 (ja) * 2009-12-29 2011-07-07 協和発酵キリン株式会社 四環系化合物
CN102746219A (zh) * 2012-07-02 2012-10-24 盛世泰科生物医药技术(苏州)有限公司 一种2-羧基-3-溴吡啶盐酸盐的合成方法
US10981918B2 (en) 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3730258A1 (de) 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
JPH01161245A (ja) 1987-12-18 1989-06-23 Canon Inc 電子写真感光体
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5093210A (en) 1989-06-30 1992-03-03 Ricoh Company, Ltd. Electroluminescent device
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
CO4980885A1 (es) 1997-12-29 2000-11-27 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto
US7056911B1 (en) 1999-01-26 2006-06-06 Dana-Farber Cancer Institute Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
ES2384057T3 (es) 2012-06-28
BRPI0714811A2 (pt) 2014-02-18
EA200970127A1 (ru) 2009-04-28
EP2043646A2 (en) 2009-04-08
WO2008008882A2 (en) 2008-01-17
JP5189091B2 (ja) 2013-04-24
AU2007272504B2 (en) 2012-06-28
CN101489556A (zh) 2009-07-22
TW200902537A (en) 2009-01-16
US8101760B2 (en) 2012-01-24
EA014695B1 (ru) 2010-12-30
JP2009543804A (ja) 2009-12-10
EP2043646B1 (en) 2012-05-16
MX2009000583A (es) 2009-01-27
KR20090020694A (ko) 2009-02-26
US20100069425A1 (en) 2010-03-18
WO2008008882A3 (en) 2008-05-02
CA2655202A1 (en) 2008-01-17
AU2007272504A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
CL2007003501A1 (es) Un compuesto (e)-n-{3-[1-(8-cloro-11h-10-oxa-1-aza-dibenzo[a,d]ciclohepten-5-iliden)propil]-fenil}-metansulfonamida o una sal del mismo; composicion farmaceutica; y uso para el tratamiento de artritis reumatoide, asma, epoc, entre otras.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
NL2000480A1 (nl) Nieuwe farmaceutische middelen.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
CL2007003718A1 (es) Compuestos macrociclos, inhibidores selectivos del factor viia de coagulacion de serinaproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de un trastorno tromboembolico.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
DK1907037T3 (da) Medikamentdispenser.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
CL2007002888A1 (es) Compuestos derivados de n-metansulfonilamino amidas, inhibidores de metaloproteasas de matriz; composicion farmaceutica; y uso para el tratamiento de un trastorno de proliferacion celular.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
CL2007003044A1 (es) Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.